Mutants of il-21 and methods of making and using the same

By mutating IL-21 amino acids and fusing it with a PD-1 antibody, the problems of short half-life and large side effects of IL-21 drugs in tumor treatment have been solved, achieving more efficient and safer tumor treatment results.

CN119751635BActive Publication Date: 2026-06-12CHINA RESOURCES BIOPHARMACEUTICAL CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CHINA RESOURCES BIOPHARMACEUTICAL CO LTD
Filing Date
2024-12-30
Publication Date
2026-06-12

AI Technical Summary

⚠Technical Problem

Existing IL-21 drugs have problems such as short half-life, large side effects, and poor targeting when treating tumors, resulting in poor treatment effects and high systemic toxicity.

⚗Method used

By mutating amino acids in IL-21 to reduce its affinity for IL-21R and γC, and fusing it with a PD-1 antibody, a fusion protein of a PD-1 antibody and a mutant IL-21 molecule with improved stability and good drug-like properties is formed, thus optimizing its targeting and half-life in the tumor microenvironment.

🎯Benefits of technology

It significantly improved the efficacy of IL-21, reduced toxic side effects, prolonged the half-life, enhanced its activation ability on tumor cells, and improved the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119751635B_ABST
    Figure CN119751635B_ABST
Patent Text Reader

Abstract

The application discloses a mutant of IL-21 and a preparation method and application thereof. The mutant has an amino acid mutation at one or more of positions 36, 37 and 39 compared with wild-type IL-21. In some embodiments, the IL-21 is subjected to artificial disulfide bond design and removal of exposed furin cleavage sites to optimize its drugability, and finally, a PD-1 antibody and IL-21 mutant molecule fusion protein with improved stability, good drugability, good efficacy and low toxicity is obtained by fusing the PD-1 antibody.
Need to check novelty before this filing date? Find Prior Art